Loading...
XKRX
000250
Market cap3.72bUSD
Jul 25, Last price  
230,000.00KRW
1D
2.00%
1Q
60.61%
Jan 2017
1,865.81%
IPO
4,570.05%
Name

Sam Chun Dang Pharm Co Ltd

Chart & Performance

D1W1MN
P/E
P/S
24.39
EPS
Div Yield, %
Shrs. gr., 5y
1.51%
Rev. gr., 5y
2.48%
Revenues
210.92b
+9.47%
76,650,143,370104,543,010,020118,924,047,670132,062,478,624147,372,999,944160,587,122,304159,960,312,377186,602,477,367166,862,333,786167,274,903,875177,335,410,013192,668,515,620210,923,804,520
Net income
-10.92b
L+5.14%
1,340,410,7608,723,680,83011,847,855,76011,628,174,5848,711,682,67812,514,554,5938,754,480,44210,451,684,443-965,677,310-16,555,159,1615,837,527,760-10,382,721,091-10,916,104,960
CFO
21.77b
-7.07%
1,602,316,28015,941,392,11019,549,843,90017,341,884,15017,763,757,17425,291,989,76123,614,470,69131,905,113,993610,383,330-7,214,503,43713,278,998,70023,428,068,36021,770,705,370
Dividend
Dec 27, 201950 KRW/sh
Earnings
Aug 12, 2025

Profile

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. Its products include antibiotics, cures for the circulatory and respiratory system, medicines for the digestive system and ophthalmology, and anti-inflammatory. The company was founded on December 29, 1943 and is headquartered in Hwaseong-si, South Korea.
IPO date
Oct 04, 2000
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
210,923,805
9.47%
192,668,516
8.65%
177,335,410
6.01%
Cost of revenue
175,899,490
152,732,936
140,012,076
Unusual Expense (Income)
NOPBT
35,024,315
39,935,579
37,323,334
NOPBT Margin
16.61%
20.73%
21.05%
Operating Taxes
16,115,718
(271,038)
87,704
Tax Rate
46.01%
0.23%
NOPAT
18,908,597
40,206,618
37,235,630
Net income
(10,916,105)
5.14%
(10,382,721)
-277.86%
5,837,528
-135.26%
Dividends
(890,151)
(880,822)
(968,353)
Dividend yield
0.03%
0.05%
0.10%
Proceeds from repurchase of equity
71,215,115
(99)
924,501
BB yield
-2.07%
0.00%
-0.10%
Debt
Debt current
29,825,876
33,696,014
4,085,459
Long-term debt
24,766,644
25,327,863
72,504,864
Deferred revenue
44,619,947
19,207,690
7,417,537
Other long-term liabilities
12,212,162
12,467,942
9,069,465
Net debt
(81,436,939)
(66,619,549)
(48,919,117)
Cash flow
Cash from operating activities
21,770,705
23,428,068
13,278,999
CAPEX
(17,022,406)
(6,765,881)
(46,545,924)
Cash from investing activities
(23,157,648)
(8,421,494)
(53,937,909)
Cash from financing activities
65,759,144
3,386,553
13,325,212
FCF
(4,725,841)
26,637,767
21,878,163
Balance
Cash
141,916,673
92,743,977
86,248,378
Long term investments
(5,887,215)
32,899,448
39,261,062
Excess cash
125,483,268
116,010,000
116,642,669
Stockholders' equity
190,479,567
197,595,031
197,134,302
Invested Capital
330,694,299
267,750,637
216,816,917
ROIC
6.32%
16.59%
18.95%
ROCE
7.68%
10.41%
11.04%
EV
Common stock shares outstanding
23,152
22,424
22,068
Price
148,500.00
92.11%
77,300.00
76.48%
43,800.00
1.04%
Market cap
3,438,057,447
98.35%
1,733,338,328
79.33%
966,580,196
1.04%
EV
3,439,919,332
1,744,680,211
989,561,784
EBITDA
44,053,411
48,366,013
44,974,205
EV/EBITDA
78.09
36.07
22.00
Interest
382,538
2,577,066
2,793,303
Interest/NOPBT
1.09%
6.45%
7.48%